PharmAthene develops and commercializes medical countermeasures against biological and chemical weapons. PIP’s lead product development programs include: SparVax™ – a second generation recombinant protective antigen (rPA) anthrax vaccine; Recombinant BChE- a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents; and Valortim® – a fully human monoclonal antibody for the prevention and treatment of anthrax infection. For more information visit the company’s Web site at www.pharmathene.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: